image credit: Freepik

Protai Nabs $8M for AI-Powered Drug Discovery Platform

January 5, 2022


Despite the significant contribution of genome-level information to the efforts of drug R&D, this information fails to represent the functional layer of the cell reflected and dominated by proteins. This lack of functional understanding of a disease’s molecular mechanisms is one of the main shortcomings of the current drug discovery and development process.

Founded by Eran Seger and Kirill Pevzner, Protai has built an end-to-end AI-based platform that comprehensively maps the course of a disease on the protein level, enhancing the ability to observe cellular function and thereby improving the way new drugs are discovered.

Read More on HitConsultant